Immunome, Inc.IMNM

$18.74+0.21 (+1.13%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$2B

Mid-cap

+1642%

2020 — today

10-Year Price

+54%

2020 — today

52-Week Range

$8.40$26.97

Current $18.74· 56%

Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.

Valuation in context

P/E ratio

-7.8

N/A

Not meaningful — company is unprofitable

P/B ratio

3.6

Above average

Pricier than usual over the last 10 years

FCF Yield

-9.7%

Around average

Around the 10-year average

Free · No credit card needed

Get alerted when IMNM is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.